ESTRO 2024 - Abstract Book

S1387

Clinical - Head & neck

ESTRO 2024

Keywords: lymphovascular invasion, tongue cancer, prognosis

2254

Proffered Paper

Metabolic adapted radiation dose for head and neck squamous cell carcinoma

Sebastian Zschaeck 1 , Emily Kukuk 1 , Elia Lombardo 2 , Sebastian Marschner 2 , Marcus Beck 1 , Felix Mehrhof 1 , Yimin Li 3 , Qin Lin 4 , Christian Furth 5 , Vincent Gregoire 6 , Nathalie L Albert 7 , Mechthild Krause 8 , Michael Baumann 9 , Joanna Kazmierska 10 , Paulina Cegla 11 , Witold Cholewinski 11 , Iosif Strouthos 12 , Klaus Zöphel 13 , Guillaume Landry 2 , Claus Belka 2 , Daniel Zips 1 , Frank Hofheinz 14 1 Charité university hopsital, Radiation Oncology, Berlin, Germany. 2 Ludwig-Maximilians-University (LMU) Munich, Radiation Oncology, Munich, Germany. 3 Xiamen Cancer Center, Radiation Oncology, Xiamen, China. 4 Xiamen Cancer Center, Nuclear Medicine, Xiamen, China. 5 Charité university hopsital, Nuclear Medicine, Berlin, Germany. 6 Leon Bérard Cancer Center, Radiation Oncology, Lyon, France. 7 Ludwig-Maximilians-University (LMU) Munich, Nuclear Medicine, Munich, Germany. 8 Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Radiation Oncology, Dresden, Germany. 9 German Cancer Research Center (DKFZ), Heidelberg, DKFZ, Heidelberg, Germany. 10 Greater Poland Cancer Centre, Radiation Oncology, Poznan, Poland. 11 Greater Poland Cancer Centre, Nuclear Medicine, Poznan, Poland. 12 German Oncology Center, European University Cyprus, Radiation Oncology, Limassol, Cyprus. 13 Klinikum Chemnitz gGmbH, Nuclear Medicine, Chemnitz, Germany. 14 Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany

Purpose/Objective:

In 2016 Scott and colleagues presented the concept of genomic adapted radiation dose by integrating a radiosensitivity gene signature and radiation dose into the linear quadratic model [1].

Biopsy based gene signatures may not reflect tumor heterogeneity, an important parameter of radiosensitivity. We therefore aimed to integrate metabolic tumor data from 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) CT imaging of the primary tumor into a metabolic adapted radiation dose (MARD) as a proof of concept.

Material/Methods:

A multicenter cohort of non-metastatic head and neck squamous cell carcinoma (HNSCC) patients with FDG-PET CT staging was analyzed. The total lesion glycolysis (TLG) as a product of the metabolic tumor volume (MTV) and SUV mean of 938 head and neck squamous cell carcinoma (HSCC) patients receiving primary (chemo)radiation and 294 patients receiving primary surgery were calculated. MTV delineation was performed as previously described [2]. The MARD or shamMARD for surgical patients was calculated by integrating TLG and the applied / sham radiation dose into the linear quadratic model as described in [1].